Drug intelligence / Profile preview

LMP766

Development stage: Discontinued
Lead developer: Locus Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

LMP766 is an orally bioavailable small molecule inhibitor of tumor necrosis factor-alpha (TNF-alpha) synthesis. Developed by Locus Pharmaceuticals using their proprietary computational fragment-based drug design platform, LMP766 was designed to treat inflammatory conditions such as Crohn's disease and rheumatoid arthritis. Unlike monoclonal antibody biologics that neutralize circulating TNF-alpha protein, LMP766 acts intracellularly to inhibit the production of TNF-alpha at the cellular level. Clinical development reached Phase 2 for the treatment of Crohn's disease; however, the program was ultimately terminated, and the developer, Locus Pharmaceuticals, ceased operations around 2010.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on LMP766.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LMP766.

Explore the full profile